PARP1 and nonpapillary renal cell carcinoma: (44) proposed that poly ADP-ribose polymerase-1 (PARP1) could be a marker of the efficacy of immunotherapy for patients with PBRM1-mutant ccRCC, the higher expression of which suggested poorer prognosis and higher drug resistance. In our study, 46 differentially expressed GILncs between genome-unstable and genome-stable-like groups were found, among which LINC00460, AL139351.1, and AC156455.1 were validated as significant independent prognostic factors and considered for the construction of the risk model.